^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IL33 (Interleukin 33)

    i
    Other names: Interleukin 33, IL1F11, NF-HEV, Nuclear Factor From High Endothelial Venules, Nuclear Factor For High Endothelial Venules, Interleukin-1 Family Member 11, DVS27-Related Protein, Interleukin-33, C9orf26, DVS27, Chromosome 9 Open Reading Frame 26 (NF-HEV), Interleukin-1 Family, Member 11, IL-1F11, NFEHEV, NFHEV, IL-33, IL33
    Associations

    News

    Trials
    4d
    Persistent Gene Activation as a Molecular Signature of Ulcerative Colitis Progression to Colorectal Cancer. (PubMed, Dig Dis Sci)
    We identified seven genes that are persistently upregulated during the progression from HC to UC and CAC. These genes influence neutrophils and inflammatory/tumorigenic pathways. The upregulation of PD-L1 in neutrophils suggests that neutrophil-mediated immune suppression may contribute to CAC progression, supporting their potential as molecular markers and therapeutic targets for early intervention in UC-related cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • S100A8 (S100 Calcium Binding Protein A8) • IL33 (Interleukin 33) • MMP3 (Matrix metallopeptidase 3)
    |
    PD-L1 expression
    6d
    Systemic sclerosis-associated pulmonary arterial hypertension and pulmonary fibrosis: exploring biomarker discriminators with advanced omics in a Caucasian cohort. (PubMed, Front Immunol)
    Biomarkers of SSc-PAH were linked to nicotinate and nicotinamide, as well as tryptophan metabolism, whereas those of SSc-PF reflected immune cell infiltration and fibrosis. These findings highlight the potential biomarker panels for diagnosis and targeted therapeutic development.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • IL33 (Interleukin 33)
    7d
    Retraction: Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1. (PubMed, Front Pharmacol)
    [This retracts the article DOI: 10.3389/fphar.2024.1345645.].
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MUC1 (Mucin 1) • IL33 (Interleukin 33)
    11d
    Endothelial dysfunction and cardiac damage indicators in patients with β-thalassemia major under iron-chelation therapy. (PubMed, Ther Adv Hematol)
    HO-1 showed a significant inverse correlation with HMGB-1 (r = -0.405, p = 0.001), KEAP1 was positively correlated with sST2 (r = 0.282, p = 0.029), and GPX4 was correlated with FGF21 (r = 0.255, p = 0.049); no other significant associations were found. β-thalassemia major patients exhibit significant endothelial and cardiac injury markers, altered lipid profiles, and selective upregulation of antioxidant and ferroptosis-related genes.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • IL10 (Interleukin 10) • GPX4 (Glutathione Peroxidase 4) • HMGB1 (High Mobility Group Box 1) • IL18 (Interleukin 18) • FGF21 (Fibroblast Growth Factor 21) • SLC7A11 (Solute Carrier Family 7 Member 11) • VCAM1 (Vascular Cell Adhesion Molecule 1) • IL33 (Interleukin 33) • ST2 (Suppression Of Tumorigenicity)
    12d
    Categorization of chronic pain subtypes and contributing biomarkers in heart failure. (PubMed, Eur J Cardiovasc Nurs)
    In this study, chronic pain and its association with underlying biomarkers were characterized. Future research with a larger sample is needed to understand the unique contributions of biomarkers with targeted pain phenotypes.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • BDNF (Brain Derived Neurotrophic Factor) • CRP (C-reactive protein) • IL33 (Interleukin 33) • LEP (Leptin)
    14d
    Hepatoprotective Effect of Floccularia luteovirens (Agaricomycetes) Polysaccharides on Alcohol-Induced Acute Liver Injury in Mice. (PubMed, Int J Med Mushrooms)
    At the same time, they could significantly increase the levels of catalase (CAT) and glutathione peroxidase (GSH-Px), enhancing the antioxidant capacity of the body, which confirmed the protective therapeutic effects of FLPs against oxidative stress and inflammation in alcoholic liver injury. The Western blot assay investigated the effect of FLPs on the NF-κB/NLRP3 signaling pathway in the liver tissues of mice with alcoholic liver injury, indicating that its mechanism of action may be to inhibit the expression of inflammatory factors such as IL-1β and suppress the NF-κB/NLRP3 inflammasome signaling pathway to achieve antioxidant and anti-inflammatory effects.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CAT (Catalase) • IL33 (Interleukin 33)
    18d
    Inflammatory profile associated with hyperglycemia in children with type 1 diabetes. (PubMed, J Diabetes Complications)
    A broad range of inflammatory mediators are correlated with HbA1c in children with T1D. These inflammatory changes precede development of T1D complications, suggesting that possible pathophysiologic involvement should be investigated.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MMP2 (Matrix metallopeptidase 2) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • CCL8 (C-C Motif Chemokine Ligand 8) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • CCL27 (C-C Motif Chemokine Ligand 27) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL13 (Interleukin 13) • IL21 (Interleukin 21) • IL4 (Interleukin 4) • MMP1 (Matrix metallopeptidase 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • IL33 (Interleukin 33) • LIF (LIF Interleukin 6 Family Cytokine)
    21d
    Convergent Multistage Evidence Implicates the CCR2-Artemin Immune-Inflammation Axis in Acute Myeloid Leukemia. (PubMed, Mediators Inflamm)
    Pathway analyses highlighted membrane-proximal processes (external plasma membrane and IgG binding) and a 16p11.2 signal. This integrative analysis identified CCR2-ARTN as a mechanistically supported immune-inflammation axis contributing to AML risk, offering a potential therapeutic target and warrants direct validation in primary CD62L + myeloid DCs.
    Journal • IO biomarker
    |
    CCR2 (C-C Motif Chemokine Receptor 2) • CD40LG (CD40 ligand) • IL33 (Interleukin 33) • MTHFD2 (Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2)
    22d
    Research progress of Type II immune responses in cancer therapy (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
    This "pro-tumor vs. anti-tumor" duality underscores the pivotal yet paradoxical role of Type II immunity in tumor immunoregulation. Here, we systematically review the dual functions of Type II immune responses in tumor immunity and their translational potential for next-generation cancer immunotherapy.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • STAT6 (Signal transducer and activator of transcription 6) • IL4 (Interleukin 4) • IL5 (Interleukin 5) • IL33 (Interleukin 33)
    23d
    The MDM2-IL-33 Axis Promotes Gastric Tumorigenesis via K63 Ubiquitination-Dependent ERK/JNK Activation. (PubMed, Cell Biochem Funct)
    Crucially, MDM2 overexpression promoted tumor growth, which was effectively reversed by transfection with si-MDM2. These findings firmly established MDM2 as a crucial regulator of IL-33 stability and highlighted the significant therapeutic potential of targeting the MDM2-IL-33 interaction to impede gastric cancer progression.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MDM2 (E3 ubiquitin protein ligase) • CASP3 (Caspase 3) • IL33 (Interleukin 33)
    24d
    The effect of transperineal template prostate biopsy (TTPB) on selective serum biomarkers: a clinical-pilot observational study. (PubMed, Int Urol Nephrol)
    The significant increases in serum PDGF-AA and TGF-α, and significant decreases in serum EGF and Flt3 ligand could be explained by post-procedural inflammatory or paraneoplastic mechanisms. Further research into these biomarkers with larger cohorts may enable further understanding of their role pre- and post-operatively in TTPB and their correlation with clinical outcomes. This may be used to develop a clinical tool to predict or identify patients at risk of early post-TTPB complications.
    Observational data • Journal • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • VEGFA (Vascular endothelial growth factor A) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL23 (Chemokine (C-C motif) ligand 23) • CD40LG (CD40 ligand) • TGFA (Transforming Growth Factor Alpha) • IL33 (Interleukin 33)
    25d
    Exploring the Potential Role of Interleukin-33 in Inducing Eosinophil-Mediated Fibrosis in Hepatic Alveolar Echinococcosis. (PubMed, Front Biosci (Landmark Ed))
    IL-33 contributed to microenvironmental fibrosis within AE lesions via eosinophil-mediated mechanisms, highlighting a potential therapeutic target to improve chemotherapy efficacy in patients with AE.
    Journal
    |
    IL33 (Interleukin 33) • ST2 (Suppression Of Tumorigenicity)